LONDON, March 27, 2025 /PRNewswire/ — On March 25, 2025, the Tokyo District Court granted the Japanese government’s request for a dissolution order against the Family Federation for World Peace and Unification (FFWPU), previously known as the Unification Church. This decision has raised…
Month: March 2025
TOKYO, March 27, 2025 /PRNewswire/ — Tokyo Electron Ltd. (TEL; Head Office: Minato-ku, Tokyo; President: Toshiki Kawai) is pleased to announce that it has signed a multi-year official partnership agreement with the Los Angeles Dodgers, a Major League Baseball (MLB) team in the National…
CLEVELAND, March 27, 2025 /PRNewswire/ — Affiliates of Peppertree Capital Management, Inc. (“Peppertree”) obtained a unanimous arbitration award in excess of $354 million against Terra Towers Corp., DT Holdings, and businessman Jorge Hernandez, personally (“Respondents”), the law firm of…
Collaborative Entity Formed by Princeton University, The Rockefeller University, Weill Cornell Medicine and the Ludwig Institute for Cancer Research to Investigate the Interplay Between Nutrition, Metabolism and Immunotherapy NEW YORK and PRINCETON, N.J., March 27, 2025 /PRNewswire/ –…
Data highlights preclinical efficacy and safety of GNX1021, a novel glycan-targeting ADC, in gastric cancer models NEW TAIPEI CITY, Taiwan, March 27, 2025 /PRNewswire/ — GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the…
Christopher Nolan shares his insights on the innovative blend of science and cinema that earned him the prestigious Stephen Hawking Medal for Science Communication, in an exclusive discussion with Nobel Laureate Kip Thorne and STARMUS cofounder and director Dr. Garik Israelian. Created by…
SHENZHEN, China, March 27, 2025 /PRNewswire/ — RoboSense (2498.HK), a pioneering AI-driven robotics technology company, and LionsBot, a renowned robotics developer from Singapore, have announced a strategic partnership, joining forces to enhance the visual perception capabilities of…
– ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting – Actinium is establishing radiopharmaceutical manufacturing infrastructure in 2025 to support expanding…
Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025 Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients…
The Company continues to work diligently to file its 2024 SEC reports ST. LOUIS , March 27, 2025 /PRNewswire/ — Latch, Inc. (“Latch” or the “Company”), soon to be DOOR, today announced that on March 26, 2025, the Company filed its Annual Report on Form 10-K for the year ended December…